Business context and reporting period
Nanophase Technologies Corporation’s unaudited Form 10-Q covers the quarter ended March 31, 2024. The consolidated results include its wholly owned Solésence subsidiary. The company focuses on beauty and skin-health products and ingredients, alongside medical diagnostics and legacy advanced-materials markets. The filing’s index contains an apparent “Quarter Ended March 31, 2022” typo; the report cover and financial statements identify the period as March 31, 2024.
Financial performance and position
Amounts below are in thousands of dollars, except per-share data and percentages.
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Total revenue | $9,868 | $9,457; up 4.3% |
| Gross profit / margin | $3,580 / 36.3% | $2,149 / 22.7% |
| Operating income (loss) | $1,111 | $(1,004) |
| Net income (loss) | $893; $0.02 per basic and diluted share | $(1,159); $(0.02) per share |
| Operating cash flow | $(3,855) | $(782) |
| Cash at quarter-end | $2,018 | $1,094 at March 31, 2023 |
| Current assets / current liabilities | $22,077 / $12,177; current ratio 1.81 | $16,302 / $15,589 at December 31, 2023; ratio 1.05 |
Revenue growth came from Solésence finished products, partly offset by lower personal-care ingredient and medical-diagnostics sales. Product revenue was $9,772, and other revenue was $96. Lower manufacturing costs—primarily Solésence production efficiencies—supported the gross-margin improvement. Research and development expense was $910 versus $1,003; selling, general and administrative expense was $1,559 versus $2,150, including approximately $505 less in legal costs.
Cash used in operations was driven principally by working-capital investment, including a $3,250 increase in inventory and a $1,760 increase in trade receivables. Investing cash use was $85. Financing provided $4,236, including $6,000 from preferred-stock issuance, partly offset by debt repayments and other credit-facility activity.
At March 31, the balance sheet reported $850 outstanding on the related-party accounts-receivable line, $5,200 on the inventory facility, and $1,000 of related-party term debt: $7,050 in total, excluding operating lease obligations. The company also reported $10,107 of current and long-term operating lease obligations. The related-party facilities bear stated rates of 9.25%; their maturities were extended to October 1, 2025. The $2,000 bridge note was repaid in February.
Material changes and capital structure
- Solésence revenue grew to $8,104 from $5,044. Personal Care Ingredients revenue fell to $1,376 from $3,544, and Advanced Materials revenue fell to $388 from $869. The category table labels both columns “2023,” but its surrounding text and total figures indicate the second column is 2024; investors should verify the source presentation.
- Four customers accounted for 65% of revenue, up from 62%; the largest represented 35%, versus 5% a year earlier. Receivables from those four customers totaled $4,320.
- On March 1, the company issued Strandler, LLC 15,000 Series X preferred shares for $6,000. They carry a $6,000 liquidation preference, no dividends or voting rights, and are convertible at the holder’s option into 1,000 common shares each if the company obtains shareholder approval to increase authorized common shares from 60 million to 95 million. If that amendment is not filed by August 1, 2024, the holder may seek redemption at $420 per preferred share. A change in control also triggers an optional redemption right.
- Common shares outstanding increased from 49,627,254 at year-end to 54,860,984 at March 31, largely reflecting issuance of 5,233,730 shares. The preferred shares are presented as mezzanine equity.
Outlook, risks, and unusual items
- Management expects 2024 capital spending of $3 million to $6 million for known needs, with actual spending dependent on project outcomes, growth, and access to funding. Funding sources may include operating profits, existing credit facilities, and potential new debt.
- Management says margins may improve with higher production volumes and better absorption of fixed costs, but margin growth is not assured. Results depend on sales mix, volume, manufacturing scale-up, cost control, and the ability to pass raw-material and wage inflation through to customers. The company plans to add manufacturing capacity and fixed costs through 2024.
- The company reports seasonal and customer-driven demand variability, reduced medical-diagnostics demand, reliance on a limited number of customers, and potential difficulty obtaining working capital or passing through input-cost increases. It has approximately $50 million of federal net operating loss carryforwards, some of which may be limited by future ownership changes.
- After quarter-end, Nanophase and BASF settled their New Jersey litigation; dismissal with prejudice was filed April 11. The amended supply agreement preserves BASF exclusivity for specified zinc-oxide materials while permitting certain Solésence finished products and customer-specific dispersions. Nanophase will use commercially reasonable efforts to develop a modified zinc-oxide product for BASF. Separate supply-agreement performance provisions could require equipment sales to BASF and, if triggered, result in significant lost revenue and replacement-capacity costs.
- Management concluded disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Reconcile the preferred-stock conversion disclosures: the terms provide for up to 15 million common shares (15,000 preferred shares multiplied by 1,000), while the EPS note says 5,109,890 preferred-related weighted-average shares were included and separately refers to 15 million potential shares. Confirm the actual conversion calculation and dilution implications.
- Track shareholder approval and filing of the authorized-share increase by August 1, 2024, and assess the potential $6.3 million redemption obligation if the preferred holder exercises its rights.
- Assess liquidity and working-capital needs in light of $2.0 million cash, quarterly operating cash use of $3.9 million, rising inventory and receivables, and dependence on related-party credit.
- Monitor customer concentration, Solésence growth, the decline in ingredient and advanced-materials sales, and the BASF agreement’s operational and supply-performance requirements.
- Confirm the apparent period-label errors in the index and revenue-category table against the filed financial statements or XBRL data.